Table V.
Individual characteristics of the patients (n=8).
| Patient number | Sex | Age (years) | ECOG PS | Histology | T | N | M | Overall response | PFS (months) | Treatment after S.1 | OS (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Female | 84 | 1 | Ad | 3 | 3 | 1a | SD | 1.2 | GEM→VNR→RT→DTX | 13.6 |
| 2 | Male | 75 | 1 | Ad | 1 | 0 | 1b | PD | 1.8 | PEM+BEV→DTX | 17.1 |
| 3 | Male | 81 | 1 | Ad | 4 | 3 | 1b | PD | 1.9 | DTX+BEV | 7.6 |
| 4 | Male | 75 | 1 | Ad | 1b | 0 | 1a | PD | 1.5 | DXT→nab-PTX→VNR | 31.1 |
| 5 | Male | 82 | 0 | Sq | 4 | 1 | 1a | PD | 0.9 | WBRT | 5.8 |
| 6 | Male | 76 | 0 | Ad | 4 | 3 | 1b | PD | 1.1 | DTX→VNR→DTX | 6.5 |
| 7 | Male | 75 | 1 | Sq | 4 | 2 | 1a | PD | 1.4 | Erlotinib | 2.8 |
| 8 | Female | 85 | 1 | NOS | 2a | 3 | 1b | PD | 1.5 | RT | 3.0 |
ECOG PS, Eastern Cooperative Oncology Group performance status; Ad, adenocarcinoma; Sq, squamous cell carcinoma; NOS, not otherwise specified; SD, stable disease; PD, progressive disease; PFS, progression free survival; OS, overall survival; T, tumor; N, node; M, metastasis; GEM, gemcitabine; VNR, vinorelbine; RT, radiation therapy; nab-PTX, nab-paclitaxel; WBRT, whole-brain radio therapy; PEM, pemetrexed; BEV, bevacizumab; DTX, docetaxel.